Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas
Status:
Terminated
Trial end date:
2018-09-12
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well giving hypofractionated radiation therapy together with
temozolomide and bevacizumab works in treating patients with high-grade glioblastoma
multiforme or anaplastic glioma. Specialized radiation therapy, such as hypofractionated
radiation therapy, that delivers a high dose of radiation directly to the tumor may kill more
tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as
temozolomide, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can
block tumor growth in different ways. Some block the ability of tumor to grow and spread.
Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving
hypofractionated radiation therapy together with temozolomide and bevacizumab may kill more
tumor cells.